RUBICON RESEARCH LIMITED (RUBICON) financials

RUBICON RESEARCH LIMITED (RUBICON) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]

Market Cap: ₹25,038Cr.
Current Price: ₹1,513
Stock P/E: 106
ROE: 18.7%
ROCE: 21.0%
Book Value: ₹82.0
Dividend Yield: 0.10%
52W High / Low: ₹1,899/571

In Jun 2026, RUBICON RESEARCH LIMITED (RUBICON) reported sales ₹428 Cr and net profit ₹82 Cr.

Annual TTM: sales ₹1,456 Cr, net profit ₹235 Cr.

Shareholding: Promoters 59.76% (Jun 2026), FIIs 7.52% (Jun 2026), DIIs 9.43% (Jun 2026), Public 23.29% (Jun 2026), No. of Shareholders 43,254% (Jun 2026).

RUBICON quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	255	245	301	278	336	302	390	428
Expenses	186	181	240	215	257	239	284	303
Operating Profit	68	64	61	63	79	62	106	125
OPM %	27%	26%	20%	23%	24%	21%	27%	29%
Other Income	3	2	12	1	2	4	4	2
Interest	6	7	11	9	9	8	5	6
Depreciation	7	8	9	8	10	10	10	11
Profit before tax	58	51	54	47	62	50	94	111
Tax %	25%	25%	25%	26%	26%	25%	26%	25%
Net Profit	43	38	40	35	46	37	70	82
EPS in Rs	2.82	2.51	2.61	2.28	2.97	2.26	4.24	4.99
Raw PDF	—	—	—	—	—	—	—	—

RUBICON profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	263	331	400	394	631	1,074	1,306	1,456
Expenses	173	220	360	375	557	803	994	1,083
Operating Profit	90	111	40	18	73	271	312	372
OPM %	34%	34%	10%	4.7%	12%	25%	24%	26%
Other Income	18	11	17	25	26	19	10	12
Interest	6	9	9	19	31	34	31	28
Depreciation	18	28	32	36	35	32	38	40
Profit before tax	84	85	17	-11	34	223	253	316
Tax %	29%	38%	1%	53%	29%	25%	26%	—
Net Profit	59	53	17	-17	24	168	188	235
EPS in Rs	116.53	104.46	32.90	-33.31	1.60	10.87	11.40	14.46
Dividend Payout %	2%	0%	0%	-2%	1%	0%	13%	—

RUBICON balance sheet (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5	5	5	5	15	15	17
Reserves	350	406	424	281	461	652	1,337
Borrowings	30	93	169	320	412	408	276
Other Liabilities	59	65	81	144	129	265	346
Total Liabilities	445	570	678	750	1,017	1,341	1,976
Fixed Assets	151	177	181	199	232	259	416
CWIP	2	4	3	25	10	6	26
Investments	35	32	19	0	34	36	43
Other Assets	256	356	476	526	741	1,040	1,490
Total Assets	445	570	678	750	1,017	1,341	1,976

RUBICON cash flows (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	9	47	-71	-75	83	30	39
Cash from Investing Activity	-84	-29	-43	-32	-130	-10	-270
Cash from Financing Activity	76	52	65	123	46	-34	297
Net Cash Flow	1	70	-49	16	-1	-15	66
Free Cash Flow	-41	47	-71	-119	27	-40	-156
CFO/OP	40%	72%	-156%	-394%	136%	21%	43%

RUBICON shareholding pattern (%)
Category	Dec 2025	Mar 2026	Jun 2026
Promoters	59.99%	59.86%	59.76%
FIIs	7.99%	7.54%	7.52%
DIIs	9.45%	10.02%	9.43%
Public	22.57%	22.57%	23.29%
No. of Shareholders	31,914	33,738	43,254

RUBICON key ratios
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	194	169	213	209	146	170	199
Inventory Days	360	373	203	609	309	305	365
Days Payable	213	212	206	353	167	218	275
Cash Conversion Cycle	341	330	210	465	288	258	290
Working Capital Days	191	168	159	75	53	110	197
ROCE %	—	21%	5%	1%	9%	26%	21%

RUBICONUpdated 13 Oct 2026, 14:59

Rubicon Research Limited

RUBICONUpdated 13 Oct 2026, 14:59

Market Cap

₹25,038Cr.

Current Price

₹1,513

High / Low

₹1,899/571

Stock P/E

106

ROE18.7%

ROCE21.0%

Book Value₹82.0

Face Value₹1.00

Dividend Yield0.10%

About

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Sep 2024	255	6	186	3	7	58	25	43	2.82
Dec 2024	245	7	181	2	8	51	25	38	2.51
Mar 2025	301	11	240	12	9	54	25	40	2.61
Jun 2025	278	9	215	1	8	47	26	35	2.28
Sep 2025	336	9	257	2	10	62	26	46	2.97
Dec 2025	302	8	239	4	10	50	25	37	2.26
Mar 2026	390	5	284	4	10	94	26	70	4.24
Jun 2026	428	6	303	2	11	111	25	82	4.99

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2020	263	6	173	18	18	84	29	59	116.53
Mar 2021	331	9	220	11	28	85	38	53	104.46
Mar 2022	400	9	360	17	32	17	1	17	32.9
Mar 2023	394	19	375	25	36	-11	53	-17	-33.31
Mar 2024	631	31	557	26	35	34	29	24	1.6
Mar 2025	1074	34	803	19	32	223	25	168	10.87
Mar 2026	1306	31	994	10	38	253	26	188	11.4
TTM	1456	28	1083	12	40	316	—	235	14.46

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	59.76%
FIIs	7.52%
DIIs	9.43%
Public	23.29%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2025	59.99%	7.99%	9.45%	22.57%
Mar 2026	59.86%	7.54%	10.02%	22.57%
Jun 2026	59.76%	7.52%	9.43%	23.29%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2020	5	350	30	59	445	151	2	35	256	445
Mar 2021	5	406	93	65	570	177	4	32	356	570
Mar 2022	5	424	169	81	678	181	3	19	476	678
Mar 2023	5	281	320	144	750	199	25	0	526	750
Mar 2024	15	461	412	129	1017	232	10	34	741	1017
Mar 2025	15	652	408	265	1341	259	6	36	1040	1341
Mar 2026	17	1337	276	346	1976	416	26	43	1490	1976

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2020	9	-84	76	1
Mar 2021	47	-29	52	70
Mar 2022	-71	-43	65	-49
Mar 2023	-75	-32	123	16
Mar 2024	83	-130	46	-1
Mar 2025	30	-10	-34	-15
Mar 2026	39	-270	297	66

Key ratios

Historical financial ratios

Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	194	169	213	209	146	170	199
Inventory Days	360	373	203	609	309	305	365
Days Payable	213	212	206	353	167	218	275
Cash Conversion Cycle	341	330	210	465	288	258	290
Working Capital Days	191	168	159	75	53	110	197
ROCE %	—	21%	5%	1%	9%	26%	21%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of RUBICON RESEARCH LIMITED (RUBICON)?

The reported market capitalisation for RUBICON RESEARCH LIMITED (RUBICON) is ₹25,038Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of RUBICON?

The current price shown for RUBICON RESEARCH LIMITED (RUBICON) on Fincrux is ₹1,513 with a 52-week high/low of ₹1,899/571.

What is the P/E ratio of RUBICON RESEARCH LIMITED (RUBICON)?

The stock P/E for RUBICON RESEARCH LIMITED (RUBICON) is 106 on Fincrux, with ROE at 18.7% and ROCE at 21.0%.

What were RUBICON latest quarterly results?

For Jun 2026, RUBICON RESEARCH LIMITED (RUBICON) reported sales ₹428 Cr and net profit ₹82 Cr (figures in ₹ crore unless noted).

What are RUBICON annual sales and net profit?

For TTM, RUBICON RESEARCH LIMITED (RUBICON) shows sales of ₹1,456 Cr and net profit of ₹235 Cr on the Fincrux profit & loss statement.

Who owns RUBICON RESEARCH LIMITED (RUBICON)?

Latest shareholding for RUBICON RESEARCH LIMITED (RUBICON) on Fincrux: Promoters 59.76% (Jun 2026), FIIs 7.52% (Jun 2026), DIIs 9.43% (Jun 2026), Public 23.29% (Jun 2026), No. of Shareholders 43,254% (Jun 2026).

Where can I find RUBICON RESEARCH LIMITED (RUBICON) financials?

RUBICON RESEARCH LIMITED (RUBICON) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show RUBICON balance sheet and cash flow?

Yes. The RUBICON RESEARCH LIMITED (RUBICON) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 14:59